Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page.

“Our steadfast commitment to science and innovation has allowed us to build something special at Bonafide Health and we’ve been looking for the right partner to grow the business and reach more women that need support. Pharmavite is that partner.” Michael Satow Co-Founder and CEO of Bonafide Health


Pharmavite acquires menopause supplement brand Bonafide Health in $425M deal.

Orchid introduces whole genome sequencing reports for embryos after raising $12M in funding.

Poland-based MIM Fertility secures $2M in seed funding to advance its AI-enabled IVF solutions.

hey freya secures $500K in angel funding to advance women’s wellness through doctor-formulate supplements.

PCORI invests $80.5M in maternal health research to combat inequities.

Bayer and CrossBay Medicalcollaborate on development of novel IUD inserter.

Metabolon wins an NIH grant to develop a test to improve PCOS diagnostic accuracy.

The US National Menopause Foundationlaunches new Women’s Midlife Health Policy Institute.

Mosie Baby achieves FDA Class II clearance for at-home intravaginal insemination kit.

In the Know

Embracing Radical Innovation in Women’s Health (Femtech Insider)

Advancing Fertility Tracking with Sweat Biosensor Technology (Femtech Insider)

Pap smear photo wins BeReal’s ‘Realest Person on Earth’ Campaign (Femtech Insider)

How Oasi Care Wants to Reduce Birth Ruptures with a Simple Yet Effective Solution (Femtech Insider)

Birth Isn’t Just About the Baby: Next-Generation Postpartum Care Is Born (Well & Good)

Menopause policies: say yah boo to taboo and raise productivity (Financial Times)

Women at the margins: The urgent need for a revolution in U.S. healthcare (Fast Company)

You can’t even pay people to have more kids (Vox)

Climate, public health crises and fertility (Penn Today)

Show CommentsClose Comments

Leave a comment